Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cytokines in the clinic].

R Obrist1

  • 1Departement Innere Medizin, Universität, Kantonsspital Basel.

Helvetica Chirurgica Acta
|January 1, 1990
PubMed
Summary

Recombinant cytokines, like interferon alpha, show promise for treating cancers with fewer side effects than traditional chemotherapy. Further research is needed to define the optimal use of these novel biological therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical management of epithelial ovarian cancer at community hospitals: A population-based study.

Journal of surgical oncology·2000
Same author

How CA 125 is used in routine clinical practice.

European journal of cancer (Oxford, England : 1990)·2000
Same author

Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK).

European journal of cancer (Oxford, England : 1990)·1999
Same author

[15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].

Praxis·1998
Same author

[Secondary prevention of cancer].

Praxis·1998
Same author

[Ovarian cancer: the symptoms and pathology. The cases of the Cantonal Cancer Registry (1989-1995)].

Schweizerische medizinische Wochenschrift·1998

Area of Science:

  • Biotechnology and immunology
  • Cancer therapy research
  • Pharmacology of novel agents

Context:

  • Recombinant cytokines have been in clinical evaluation for years.
  • Interferon alpha is approved for Kaposi's sarcoma and hairy cell leukemia.
  • Emerging cytokine therapies are under investigation for broader clinical applications.

Purpose:

  • To review the current status and future potential of recombinant cytokines in clinical practice.
  • To highlight the therapeutic promise and challenges of cytokine-based treatments.
  • To discuss the development pipeline for novel immunomodulatory agents.

Summary:

  • Recombinant cytokines offer potential therapeutic advantages over conventional cytostatics, including novel effects and reduced toxicity.
  • Interferon alpha is an established therapy, while other cytokines like interleukin-2 and tumor necrosis factor are in experimental stages.
  • Hemopoietic growth factors are effective but require further definition of their clinical indications.

Impact:

  • Cytokine therapy represents a significant advancement in cancer treatment, offering targeted immunomodulation.
  • Successful development of these agents could expand treatment options for various hematological and oncological conditions.
  • Further research is crucial to optimize the application and efficacy of these biological drugs.

Related Experiment Videos